Loading data for PHAR — first visit, this takes a few seconds.

알림

Pharming Group N.V. (PHAR)

NasdaqGM: PHAR · 실시간 가격 · USD

11.85

+0.17 (1.46%)

종가 기준: Aug 27, 2026, 3:52 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

1.46% (1D)

매수호가	17.34
시가총액	827.75M
매출 (ttm)	366.48M
순이익 (ttm)	9.3M
	0.06
	0.14
	83.54
	38.09
P/B (ttm)	3.06
P/S (ttm)	2.26
실적 발표일	Mar 17, 2022

매도호가	12.17
거래량	10,885
평균 거래량 (20일)	12,953
시가	11.76
전일 종가	11.68
일중 범위	11.73 - 11.97
52주 범위	9.62 - 21.34
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

PHAR 소개

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 23, 2020

직원 수 407

상장 거래소 NasdaqGM

티커 PHAR

웹사이트 https://www.pharming.com

전체 기업 정보

재무 실적

2025년 Pharming의 매출은 376.13M로, 전년 297.2M 대비 26.56% 증가했습니다. 순이익은 2.85M로, -124.08% 감소했습니다.

재무제표

어닝 서프라이즈

Pharming가 May 7, 2026에 분기 실적을 발표했습니다:

매출 $90.21M 예상치 하회 $0, 및 -3.23% 전년 대비 감소.
EPS -0.07 예상치 하회 , 및 -250.00% 전년 대비 감소.

다음 실적 발표

Pharming Group N.V.의 실적 발표 예정일은 Mar 17, 2022, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3주 전 · Simply Wall St.

Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results

Pharming Group guidance cut and half year results draw investor focus Pharming Group (ENXTAM:PHARM) has drawn fresh attention after lowering its 2026 revenue guidance by US$30 million and reporting ha...

4주 전 · GuruFocus.com

Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ...

Pharming Group (PHGUF) navigates a mixed quarter with strong Joenja growth and cost discipline, offset by Ruconest revenue declines and a lowered full-year outlook.

4주 전 · MarketBeat

Pharming Group Q2 Earnings Call Highlights

Pharming Group (NASDAQ:PHAR) reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema thera...

2개월 전 · Simply Wall St.

Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case

Pharming Group is back in focus after analysts updated their fair value estimate from €2.11 to €2.36, giving readers fresh context for how the stock is being assessed today. Recent research frames thi...

2개월 전 · Zacks

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?

DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc...

2 페이지 중 1

Pharming Group N.V. (PHAR)